行 业 及 产 业 美容护理 2025 年 07 月 13 日 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 (8621)23297818× wanglp@swsresearch.com ⚫ 本周化妆品医美板块表现弱于市场。2025 年 7 月 4 日至 2025 年 7 月 11 日期间，申 万美容护理指数上涨 1.5%，表现弱于市场。其中，申万化妆品指数上涨 2.6%，强于申 万 A 指 1.1pct；申万个护用品指数基本持平，弱于申万 A 指数 1.6pct。 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 再生药械再添两员，轻医美概念方兴未艾 看好 ——化妆品医美行业周报 20250713 - 本期投资提示： ⚫ 周观点：再生药械再添两员，轻医美概念方兴未 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-028 润本生物技术股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 股东持股的基本情况 本次减持计划实施前，润本生物技术股份有限公司（以下简称"公司"）持股5%以上股东JNRY VIII HK Holdings Limited（以下简称"JNRY VIII"）持有公司股份22,252,566股，占公司总股本的5.50%。上述股 份来源为公司IPO前取得的股份，上述IPO前取得的股份已于2024年10月17日解除限售并上市流通。 ● 减持计划的实施结果情况 2025年3月19日，公司披露了《关于持股5%以上股东减持股份计划的公告》（公告编号：2025-004）， JNRY VIII因基金投资运作需求，拟以集中竞价、大宗交易方式合计减持公司股份不超过12,137,799股 （即不超过公司总股本的3.00%），其中：通过集中竞价交易方式减持的，减持股份的总数不超过 4,045,933股（即不超过公司总股本 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-028 润本生物技术股份有限公司 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东持股的基本情况 本次减持计划实施前，润本生物技术股份有限公司（以下简称"公司"）持股 5%以上 股东 JNRY VIII HK Holdings Limited（以下简称"JNRY VIII" ）持有公司股份 22,252,566 股， 占公司总股本的 5.50%。上述股份来源为公司 IPO 前取得的股份，上述 IPO 前取得的股份 已于 2024 年 10 月 17 日解除限售并上市流通。 （公告编 ，JNRY VIII 因基金投资运作需求，拟以集中竞价、大宗交易方式合计减持公 号：2025-004） 司股份不超过 12,137,799 股（即不超过公司总股本的 3.00%），其中：通过集中竞价交易方 式减持的，减持股份的总数不超过 4,045,933 股（即不超过公司总股本的 1.00%）；通过大宗 交易方式减持的，减持股份的总数不超过 8,09 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-028 润本生物技术股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，润本生物技术股份有限公司（以下简称"公司"）持股 5%以上 股东 JNRY VIII HK Holdings Limited（以下简称"JNRY VIII"）持有公司股份 22,252,566 股， 占公司总股本的 5.50%。上述股份来源为公司 IPO 前取得的股份，上述 IPO 前取得的股份 已于 2024 年 10 月 17 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 3 月 19 日，公司披露了《关于持股 5%以上股东减持股份计划的公告》（公告编 号：2025-004），JNRY VIII 因基金投资运作需求，拟以集中竞价、大宗交易方式合计减持公 司股份不超过 12,137,799 股（即不超过公司总股本的 3.00%），其中：通过集中竞价交易方 式减持的，减持股份的总数 ...

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]

润本股份 20250618 摘要 润本公司通过多品类战略，从驱蚊、婴童护理拓展至青少年护肤市场， 并成功推出如蛋黄油面霜和婴童防晒啫喱等差异化产品，验证了其推新 能力和市场适应性。2024 年 Q4 抖音蛋黄油面霜 GMV 达 4,500 万以上， 同比增速接近 660 倍。 2025 年，润本公司重点布局驱蚊、防晒和青少年护肤三大板块。驱蚊 产品仍是支柱，防晒新品销售良好，青少年护肤产品潜力巨大。公司凭 借自有工厂、多渠道布局和新品研发能力，具备中长期投资价值。 母婴护理市场竞争分散，但润本作为头部企业，受益于品牌背书和高复 购率（如面霜类产品复购率达 50%），具有强者恒强的属性。该市场仍 有较大增长空间，等待公司进一步抢占市场份额。 公司将业务拓展至青少年护肤市场，覆盖 0-18 岁年龄段，减少了营销 挑战。青少年护肤市场潜力巨大，2023 年全网成交额约 36 亿元，公司 可通过差异化竞争和渠道运营，打造大单品。 润本在驱蚊液领域持续创新，推出定时加热、远程操控等智能产品，并 通过抖音渠道成功推广带定时功能加热器，推动业绩增长。公司选择有 潜力的细分市场，进行品类创新和拓展。 Q&A 润本公司在 20 ...

股票简称：润本股份 股票代码：603193 公告编号：2025-027 润本生物技术股份有限公司 关于召开2024年度暨2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 润本生物技术股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日披露公司 2024 年年度报告和 2025 年第一季度报告，详见上海证券交易所网站（www.sse.com.cn）。 为便于广大投资者更全面深入地了解公司 2024 年度、2025 年第一季度经营成果、财务状况， 公司计划于 2025 年 6 月 18 日召开 2024 年度暨 2025 年第一季度业绩说明会，会议时间为 14:00-15:30，会上公司将就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动方式召开，公司将针对 2024 年度、2025 年第一季度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者 普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一 ...

Investment Rating - The investment rating for the company is "Buy" with an expectation of over 10% return relative to the CSI 300 index in the next six months [11]. Core Views - The company is positioned as a leader in the life care sector, focusing on mosquito repellent and baby care products, with a diversified product line enhancing market competitiveness [5]. - The company achieved a revenue of 1.318 billion yuan in 2024, representing a year-on-year growth of 27.61%, and a net profit of 300 million yuan, up 32.80% year-on-year [5][7]. - The online sales channel has shown significant growth, particularly on platforms like Douyin, contributing to the overall revenue increase [5][7]. - The company is expected to maintain steady growth due to product innovation and channel optimization, with projected net profits of 372 million yuan, 481 million yuan, and 615 million yuan for 2025, 2026, and 2027 respectively [7][9]. Summary by Sections Company Overview - Founded in 2006, the company aims to become a global leader in life and personal care products, offering a range of items including mosquito repellent and baby care products [5]. - The company has established a broad sales network both domestically and internationally, with a strong online presence [5]. Financial Performance - In 2024, the company reported a revenue of 1.318 billion yuan, a 27.61% increase from the previous year, and a net profit of 300 million yuan, reflecting a 32.80% growth [5][9]. - The quarterly revenue breakdown for 2024 shows significant growth, particularly in Q2 and Q4, with Q4 net profit experiencing some fluctuations due to increased promotional expenses [5][7]. Product Performance - The mosquito repellent product line generated 439 million yuan in revenue in 2024, a 35.39% increase, with a gross margin improvement to 54.18% [7]. - The baby care product line achieved 690 million yuan in revenue, up 32.42%, with a gross margin of 59.81% [7]. Channel Strategy - The online sales channel contributed 970 million yuan in revenue, a 23.80% increase, while non-platform distribution revenue reached 347 million yuan, growing by 39.64% [7]. - The company is enhancing its collaboration with e-commerce platforms to optimize its market presence and improve gross margins [7]. Future Projections - The company forecasts continued revenue growth, with expected revenues of 1.710 billion yuan, 2.131 billion yuan, and 2.530 billion yuan for 2025, 2026, and 2027 respectively [9]. - The projected net profit for the next three years indicates a robust growth trajectory, with EPS expected to rise from 0.92 yuan in 2025 to 1.52 yuan in 2027 [9].

Industry Overview - The main listed companies in the maternal and infant industry include Kidswant (301078), Runben (603193), Aiyingshi (603214), Mengjie (002397), Jinfalabi (002762), Beiyinmei (002570), Keka (301009), China Feihe (06186.HK), Babytree Group (01761.HK), Goodbaby International (01086.HK), and Newman (02530.HK) [1] - The development history of China's maternal and infant industry can be divided into several stages: Exploration Period (1990s), Development Period (2000-2010), Explosion Period (2011-2018), and Integration Period (2019-present) [1][2] Development Stages - Exploration Period (1990s): Introduction of foreign parenting culture and products, with limited specialized maternal and infant stores [1] - Development Period (2000-2010): Increased acceptance of maternal and infant products, emergence of regional chain markets, and the rise of online maternal and infant communities [1] - Explosion Period (2011-2018): Rapid growth of online maternal and infant platforms and the establishment of offline stores as the primary consumption channel [1] - Integration Period (2019-present): Growth of private traffic through social media and the need for a "online + offline" shopping experience to maintain competitive advantage [2] Global Trends - The global maternal and infant industry began to flourish in the 1950s-60s, with significant growth in countries like Japan and the USA, leading to the emergence of chain brands [3] - By 1990, the maternal and infant market in developed countries matured, prompting international brands to enter markets like China, where domestic brands also began to rise [3] - The future of maternal and infant products will see increased diversification and innovation in sales channels and models to meet modern consumer demands [3] Market Share Insights - According to Grand View Research, baby cosmetics and toiletries account for 33.5% of the global baby products market, driven by the importance of hygiene and convenience for parents [7] - Baby food holds a 25.3% market share, with demand driven by urbanization, busy work schedules, and increasing parental focus on nutrition [7] Demographic Trends - The number of women of childbearing age in China is on a declining trend, decreasing from 380 million in 2011 to 310 million in 2022, with projections indicating a further decline by 2025 [9][10]

太阳能：拟1亿-2亿元回购股份用于注销 5月26日晚，太阳能（000591）发布公告称，公司拟使用自筹资金以集中竞价交易方式回购部分A股股 份，用于依法注销减少注册资本。回购资金总额不低于1亿元且不高于2亿元，回购价格不超过6.69元/ 股。 资料显示，太阳能成立于1993年4月，主营业务是光伏电站的投资运营，光伏电池、组件的研发、生产 和销售。 所属行业：公用事业–电力–光伏发电 润阳科技：拟3亿元增资上海傅利叶智能科技有限公司 5月26日晚，润阳科技（300920）发布公告称，公司拟与上海傅利叶智能科技有限公司签订《投资意向 协议》，以不超过3亿元的现金增资傅利叶，傅利叶投前估值为80亿元。 资料显示，润阳科技成立于2012年10月，主营业务是聚烯烃发泡材料的研发、生产及销售。 所属行业：基础化工–塑料–其他塑料制品 恒瑞医药：子公司SHR-4712注射液临床试验获得批准 5月26日晚，恒瑞医药（600276）发布公告称，子公司广东恒瑞医药有限公司、上海盛迪医药有限公司 收到国家药品监督管理局核准签发的SHR-4712注射液《药物临床试验批准通知书》，即将开展治疗晚 期实体瘤的临床试验。 资料显示，恒瑞医 ...